The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
This is kind of a big deal, no?
-Sprinter results Q1
-Activ 2 Q2
-Anytime EUA or government orders.
With all the new jobs recently, NIH tweeting about inf, etc, it's all looking very positive.
Ah ok, I was wondering with the recent drop out in activ 3 if it was going to be used on inpatients… apologies.
Q2 2022, is that the expected end date for Activ 2, I would have thought it would take much longer than that?
Sorry if this has already been discussed but on the nih web page, what does it mean by repurposed regarding SNG? and the end date of Q2 2022
https://www.nih.gov/activ/nih-funded-activ/activ-associated-clinical-trials
Are we expecting Activ-2 phase 3 trial for SNG to be completed by Q2?!
Emailing them now I don’t think is really needed. They said results will be early Q1 2022, we are currently in that so everything is on time and I believe they will be having enough to deal with without having to email back investors and repeating what has already been said.
Does anyone else think this video may almost be to do with Activ2… a smile to the US. many of the anti virals on that program were targeted at a certain strain of COVID. Whilst SNG is broad spectrum. Or am I reading into that too much. Almost trying to show why SNG has its place and is needed ASAP.
Sometimes people need to chill on this forum, I’m long on Synairgen, just asking a question. This was posted a few before that trade
31-Jan-22 17:14:02 192.21501 1,545 Sell* 192.00 193.00 2,970
So that’s also at 192/193… but a sell, so are you all saying that’s a mistake?
But I’d take £3 right now!
Hmm but the UK FTSE AIM equivalent price is around £3 I believe?
I always thought AIM was for companies at an early stage, but FTSE250 was when they were more established. Which is why I find it surprising BOO haven’t moved…
I presume if SNG did get into FTSE250, due to ETF’s people buy into it would cause the SP to increase even further on that alone.
The thing is synairgen isn’t a cheap drug. We know that. Someone correct me but we talking in the region of £2000 per course of tx?
But when you see the cost of intensive care, the long term harm covid causes people, the lives which can potentially be saved and the benefit for not just covid but also in tje fight against future respiratory viruses. Does that price not seem a little more justifiable?
Yes all the right signs are being given out by the company. And to add, UK life sciences have Synairgen added to their list.
Just patiently waiting now, the entire market is down, it was fairly obvious where this was heading following the news and trend this weekend. No concerns from me yet, in fact I made another small top up.
People on here are convinced this share is the next big thing. I’m fairly new to researching this company but certainly looks good.
But apart from this forum there doesn’t seem much love for this stock? I like using Twitter and YouTube to see popularity of a stock.
Does it bother anyone, or do you see it as this isn’t going to get much attention until it’s too late for investors, as in its already run up.
I had a question I wanted answering, and asked fairly. I’m not a de ramper or trying to find flaws in the company, I had a question I didn’t know the answer to.
Schrow you probably know everything there is to know about this company, hence your response. But reacting how you did to my question is probably a good reflection on who you are as a person.
Anyway, thank you all for answering my question and good luck to all synairgen investors. Be nice, we are all on the same team here.